HIV 2016: HIV and Non-Communicable Diseases — Opportunities and Challenges

Organizers

Peter Godfrey-Faussett, BA, MBBS, DTM&H, FRCP (UK)

UNAIDS

Peter Godfrey-Faussett is a professor at the LSHTM and consultant physician at the Hospital for Tropical Diseases. After training in clinical infectious diseases and molecular genetics, he spent five years leading the Zambian AIDS-related TB (ZAMBART) project, an interdisciplinary collaborative research programme between the LSHTM, Lusaka Urban District Health Management Team and the University of Zambia. Thereafter he spent a year working with the Global Tuberculosis Programme of the World Health Organization, where he was responsible for developing strategies to address the combined epidemic of TB and HIV. Following his return to London he has maintained an interest in global policies around TB and HIV and served as chairman for the Technical Review Panel of the Global Fund against AIDS, Tuberculosis and Malaria. A regular member of WHO expert groups, his research interests remain focused on the impact that the HIV epidemic is having on TB control and on interventions to reduce both diseases. He is currently seconded full-time to UNAIDS, where he is the Senior Science Adviser with a wide ranging portfolio including HIV cure, ARV-based HIV prevention, HIV vaccines and synergies between the HIV and the non-communicable disease response.

Maureen Goodenow, PhD

University of Florida Health

Jill A. Kanaley, PhD

University of Missouri

Linda Kupfer, PhD

NIH Fogarty International Center

Dr. Kupfer has spent over a decade at the Fogarty International Center (FIC) at the National Institutes of Health. She is currently a senior scientist at the Center for Global Health Studies, FIC. Dr. Kupfer recently spent two years (2011–2013) on detail at the US State Department, Office of the Global AIDS Coordinator, as a Senior Policy Advisor. In 2006, she served as the NIH Acting Director for Evaluation in the NIH Office of the Director. Dr. Kupfer's global research interests include the integration of non-communicable and communicable diseases in health delivery systems in low and middle income countries, implementation science and program evaluation, and she is particularly interested in the role of capacity building in international research. Dr. Kupfer received her bachelor's degree in Psychology from Cornell University and her MSc and PhD in Pharmacology from Columbia University before commencing a AAAS Science Diplomacy Fellowship at the State Department. Since receiving her doctorate Dr. Kupfer has held a number of posts focused on Science and Science Policy, including Program Officer for Bilateral Science Programs at the State Department and Director of Marine Biotechnology at the National Sea Grant College Program, NOAA.

Peter Lamptey, MD, DrPH, MPH

London School of Hygiene and Tropical Medicine, Centre for Global Non-Communicable Diseases

Timothy Mastro, MD, FACP, DTM&H

FHI 360

Dr. Timothy Mastro is Director of Global Health, Population & Nutrition at FHI 360, Durham, North Carolina, USA. He trained in primary care internal medicine in New York City. He is also Adjunct Professor of Epidemiology in the Gillings School of Global Public Health, University of North Carolina at Chapel Hill. Dr. Mastro oversees FHI 360's health, population and nutrition research and program science conducted in the United States and through FHI 360's offices in 50 countries around the world. Dr. Mastro joined FHI in 2008 following 20 years in scientific leadership positions at the US Centers for Disease Control and Prevention (CDC) in Atlanta. He joined CDC in 1988 as an Epidemic Intelligence Service Officer. At CDC his work addressed HIV, TB and STI prevention research and programs in the United States and in 25 countries in Asia, Africa and Latin America. During 1993–2000, he served in Bangkok as Director of the CDC HIV/AIDS collaboration with the Thai Ministry of Public Health. Dr. Mastro began his international public health career on the Thai-Cambodian border, where he served as a physician and medical coordinator of the United Nations Border Relief Operation.

Dr. Mastro is author or co-author of more than 160 published articles and book chapters and has served on several committees for the World Health Organization, UNAIDS, PEPFAR and the US National Institutes of Health. Dr. Mastro trained in internal medicine in New York City at Metropolitan Hospital and Mount Sinai School of Medicine. He studied at the London School of Hygiene and Tropical Medicine and received a DTM&H from the Royal College of Physicians of London. He is board certified in internal medicine, a fellow of the American College of Physicians, and a member of the American Epidemiological Society.

Celeste Sandoval, MHSS

UNAIDS

Sonya Dougal, PhD

The New York Academy of Sciences

Caitlin McOmish, PhD

The New York Academy of Sciences

Speakers

Anchalee Avihingsanon, MD

The HIV Netherlands Australia Thailand Research Collaboration

Steven G. Deeks, MD

University of California, San Francisco

Steven G. Deeks, MD, is a Professor of Medicine in Residence at the University of California, San Francisco (UCSF) and a faculty member in the Positive Health Program (AIDS Program) at San Francisco General Hospital. Dr. Deeks has been engaged in HIV research and clinical care since 1993. He is a recognized expert on HIV-associated immune dysfunction and its impact on HIV persistence (the "reservoir") and health during antiretroviral therapy. Dr. Deeks has published over 350 peer-review articles, editorials and invited reviews on these and related topics. He has been the recipient of several NIH grants, and one of the principal investigators of DARE (the Delaney AIDS Research Enterprise), which is a U19-funded international collaboratory aimed at developing therapeutic interventions to cure HIV infection. He is the co-chair of the "Towards an HIV Cure" International Working Group and a co-chair of the NIH Office of AIDS Research Research Toward a Cure Planning Group. He is also a member of the Office of AIDS Research Advisory Council (ORAC). He was elected to the American Society for Clinical Investigation (ASCI), and serves on the advisory board for Science Translational Medicine and eBioMedicine. In addition to his clinical and translational investigation, Dr. Deeks maintains a primary care clinic for HIV infected patients, and was recently a member of the Department on Health and Human Services Panel on Antiretroviral Guidelines for Adults and Adolescents.

Rebecca Dirks, MA

FHI360

Rebecca Dirks, MA, is a public health expert with over a decade of professional experience in program implementation, technical assistance, public health project management, and assessments of public health programs. Her expertise is in public health approaches to addressing noncommunicable disease, health service integration, HIV counseling and testing, and HIV prevention. At present Ms. Dirks serves as a Senior Technical Officer at FHI 360 in Washington, DC, where she provides technical assistance and project management for the organization's noncommunicable disease initiative. She is the Project Director of Abundant Health, a community-based hypertension and diabetes project in Vietnam and serves as a Technical Advisor for the Community-based Hypertension Improvement Project (ComHIP) in Ghana. She has contributed to a number of integrated NCD/HIV projects in African countries. Ms. Dirks has authored numerous publications on noncommunicable disease and HIV/AIDS in peer reviewed journals and presentations in international conferences. She has worked in over ten countries and is adept at working with community members and decision makers from across cultures.

Peter Godfrey-Faussett, BA, MBBS, DTM&H, FRCP (UK)

UNAIDS

Peter Godfrey-Faussett is a professor at the LSHTM and consultant physician at the Hospital for Tropical Diseases. After training in clinical infectious diseases and molecular genetics, he spent five years leading the Zambian AIDS-related TB (ZAMBART) project, an interdisciplinary collaborative research programme between the LSHTM, Lusaka Urban District Health Management Team and the University of Zambia. Thereafter he spent a year working with the Global Tuberculosis Programme of the World Health Organization, where he was responsible for developing strategies to address the combined epidemic of TB and HIV. Following his return to London he has maintained an interest in global policies around TB and HIV and served as chairman for the Technical Review Panel of the Global Fund against AIDS, Tuberculosis and Malaria. A regular member of WHO expert groups, his research interests remain focused on the impact that the HIV epidemic is having on TB control and on interventions to reduce both diseases. He is currently seconded full-time to UNAIDS, where he is the Senior Science Adviser with a wide ranging portfolio including HIV cure, ARV-based HIV prevention, HIV vaccines and synergies between the HIV and the non-communicable disease response.

Maureen M. Goodenow, PhD

University of Florida Health

Mark Harrington

Treatment Action Group

Mark Harrington was born and raised in San Francisco, CA. He studied film, photography, history and literature at Harvard, where he graduated in 1983. In 1988 he joined the AIDS Coalition to Unleash Power (ACT UP)/New York, where he was a key member of its Treatment + Data (T+D) Committee, and with whom he helped lead the 1988 "Seize Control of the FDA" and 1990 "Storm the NIH" demonstrations. In 1992 along with other members of T+D he cofounded Treatment Action Group (TAG), where he has been executive directo since 2002. He cowrote AIDS Research at the NIH: A Critical Review with Gregg Gonsalves; its recommendations were included in the NIH Revitalization Act of 1993. He cowrote Problems with Protease Inhibitor Development Plans (1995) and wrote Viral Load in Vancouver (1996). He served as a member of the U.S. panel on Guidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and Adolescents (1997-2010) and the World Health Organization (WHO) writing groups on Scaling Up Antiretroviral Therapy in Resource-Limited Settings: Treatment Guidelines for a Public Health Approach (2003, 2006), the WHO Interim policy on collaborative TB/HIV activities (2004), and Recommendations to improve the diagnosis of smear negative pulmonary and extrapulmonary TB among adults in HIV prevalent and resource constrained settings (2007). He was a member of the Global TB/HIV Working Group in the Stop TB Partnership (2003–2014) and served on New York Governor Andrew Cuomo's Ending the Epidemic Task Force (October 2014–January 2015) that developed New York's plan to end AIDS as an epidemic by 2020. Currently he is a member of the AIDS Clinical Trials Group Tuberculosis Transformative Sciences Group (ACTG TB TSG), the International AIDS Society (IAS) Stakeholders' Advisory Board for a Global Scientific Strategy Towards a Cure, and the Ending the Epidemic Subcommittee of the New York State AIDS Advisory Council. He is a member of the PEPFAR Scientific Advisory Board (SAB) and co-chairs it's TB/HIV Expert Working Group.In 1997 he was awarded a MacArthur Foundation fellowship and in 2012 the HealthGAP Evan Ruderman Global Health Justice Award.

David Hoos, MD, MPH

Mailman School of Public Health, Columbia University

Dr. David Hoos is the project director for ICAP's PHIA Project, which is conducting population-based HIV impact assessments to measure HIV incidence and viral suppression in 20 PEPFAR-supported countries. He was senior implementation director at ICAP from 2004 to 2013 and was the director of the Multicountry Columbia Antiretroviral Program (MCAP), an eight-year cooperative agreement funded by the CDC, which supported the scale-up of HIV prevention, care and treatment in Cote d'Ivoire, Ethiopia, Kenya, Mozambique, Nigeria, Rwanda, South Africa, and Tanzania. Dr. Hoos was an initial member of the MTCT Plus Secretariat at Columbia's Mailman School of Public Health and was responsible for establishing the procurement system for antiretroviral and other HIV-associated medications and diagnostics for the program sites. Dr. Hoos has been recognized as a technical expert in a number of areas related to HIV policy and programming. He served as a member of the Technical Review Panel for the Global Fund for AIDS, TB and Malaria (GFATM), as well as a co-chair for the Procurement and Supply Management Advisory Panel to the GFATM on procurement-related policy and country guidance. He has been a member of several WHO technical panels and was seconded to UNAIDS in Geneva as a treatment advocacy advisor for eight months in 2011. Dr. Hoos is a board-certified internist and holds a Master of Public Health degree.

Saye Khoo, MB, BS, MRCP, DTM&H, FRCP, MD, GDipEpi

University of Liverpool

Linda Kupfer, PhD

Fogarty International Center, NIH

Dr. Kupfer has spent over a decade at the Fogarty International Center (FIC) at the National Institutes of Health. She is currently a senior scientist at the Center for Global Health Studies, FIC. Dr. Kupfer recently spent two years (2011–2013) on detail at the US State Department, Office of the Global AIDS Coordinator, as a Senior Policy Advisor. In 2006, she served as the NIH Acting Director for Evaluation in the NIH Office of the Director. Dr. Kupfer's global research interests include the integration of non-communicable and communicable diseases in health delivery systems in low and middle income countries, implementation science and program evaluation, and she is particularly interested in the role of capacity building in international research. Dr. Kupfer received her bachelor's degree in Psychology from Cornell University and her MSc and PhD in Pharmacology from Columbia University before commencing a AAAS Science Diplomacy Fellowship at the State Department. Since receiving her doctorate Dr. Kupfer has held a number of posts focused on Science and Science Policy, including Program Officer for Bilateral Science Programs at the State Department and Director of Marine Biotechnology at the National Sea Grant College Program, NOAA.

Andrew Phillips, PhD

University College London

Andrew Phillips is Professor of Epidemiology in the HIV Epidemiology and Biostatistics Group at UCL (http://www.ucl.ac.uk/iph/research/hivbiostatistics) working on HIV observational cohorts (including EuroSIDA, D:A:D, CASCADE, COHERE), randomized trials (including INSIGHT SMART and START trials) and simulation modelling (HIV Synthesis model). Particular areas of interest have included HIV natural progression, virologic failure, drug resistance, adverse effects of ART, and the link between HIV and risk of non-AIDS diseases. He uses an individual-based simulation model of HIV transmission, progression and the effect of ART in an attempt to address public health questions not addressable in trials or analyses of observational studies, both in developed and developing country contexts. Much of his work involves close collaboration with Copenhagen HIV Programme (CHIP).

Timothy Mastro, MD, FACP, DTM&H

FHI 360

Wafaa El Sadr, MD, MPH

Mailman School of Public Health, Columbia University

Wafaa El-Sadr is University Professor of Epidemiology and Medicine and Mathilde Krim-amfAR Professor of Global Health at Columbia's Mailman School of Public Health and College of Physicians and Surgeons.

Through ICAP at Columbia University, the Center she established more than a decade ago, large scale programs have been established in sub Saharan Africa and Asia that integrate research, education, training and practice. ICAP works closely with US government agencies, international organizations, academic institutions, private sector, community-based organizations and civil society groups in the pursuit of responsive, inclusive, sustainable and innovative approaches to addressing global health threats and achieving public health impact.

Dr. El-Sadr's research interests are diverse and include research on the prevention and treatment of HIV, tuberculosis, non-communicable diseases, maternal-child health among others. She is focused on implementation science research as a means to taking discoveries to action, ensuring that the benefits of scientific discoveries are garnered by populations around the world.

She received her medical degree from Cairo University, a masters in public health from Columbia's Mailman School of Public Health and a masters in public administration from Harvard University's Kennedy School of Government. She was named as McArthur fellow and is a member of the National Academy of Medicine.

Roy Small

United Nations Development Programme

Kwasi Torpey, MD, PhD, MPH, FGCP

FHI360

Kwasi Torpey is a physician, public health program manager, researcher and an Associate Professor of Population, Family and Reproductive Health with 19 years of experience in public health programming in HIV, malaria, TB, reproductive health and non-communicable disease programs in several African countries

Professor Torpey served as Deputy Chief of Party, Technical for FHI360's USAID-funded Strengthening Integrated Delivery of HIV/AIDS (SIDHAS) project in Nigeria. Before this position, he was the Regional Senior Technical Advisor and Director, Technical Support for FHI/Zambia where he provided support to country programs in Africa. He has extensive experience in public health programming and implementation in HIV, malaria, TB and reproductive at different levels of the health care system as well as the community level in a number of African countries.

Professor Torpey has been a global thought leader in the integration of non-communicable diseases and reproductive health into HIV programming. He has published several scientific articles in international peer reviewed journals Professor Torpey received his medical training from the University of Ghana Medical School. He received his PhD from the Institute of Tropical Medicine/University of Antwerp in Belgium. He is a fellow of the Ghana College of Physicians and Surgeons.